Rapid Micro Biosystems Inc. (NASDAQ:RPID) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET

Company Participants

Michael Beaulieu - CFA Vice President, Investor Relations and Corporate Communications

Robert Spignesi - President and Chief Executive Officer

Sean Wirtjes - Chief Financial Officer

Conference Call Participants

Yuko Oku - Morgan Stanley

Noah Burhance - JPMorgan

Operator

Good day, and thank you for standing by. Welcome to the Rapid Micro Biosystems First Quarter 2022 Earnings Conference Call. [Operator Instructions]. Please be advised today's conference may be recorded. [Operator Instructions]

I'd now like to hand the conference over to your host today, Mike Beaulieu with Investor Relations.

Michael Beaulieu

Good morning, and thank you for joining the Rapid Micro Biosystems First Quarter 2022 Earnings Call. Joining me on the call are Rob Spignesi, Chief Executive Officer; and Sean Wirtjes, Chief Financial Officer.

Earlier today, we issued a press release announcing our first quarter financial results. A copy of the release is available on the company's website at rapidmicrobiome.com under Investors in the News and Events section.

Before we begin, I'd like to remind you that many statements made during this call may be considered forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements, including, but not limited to statements relating to Rapid Micro's financial condition, expectations for business development and growth, customer interest and adoption of the growth direct system and the potential impact of COVID-19 on Rapid Micro's business. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. For a list and description of the risks and uncertainties associated with Rapid Micro's business, please refer to the risk factor section of our Form 10-K filed with the Securities and Exchange Commission on March 24th, 2022. We urge you to consider these factors and you should be aware that these statements should be considered estimates only and are not a guarantee of future performance.

Also, the company's contract with the U.S. Biomedical Advanced Research and Development Authority, or BARDA, was completed in the fourth quarter of 2021. Throughout our quarterly performance discussions, we'll be excluding the non-commercial revenue impact from BARDA by comparing total 2022 revenue to commercial revenue in 2021. This conference call contains time sensitive information and is accurate only as of the live broadcast today, May 10, 2022. Rapid Micro disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements because of new information, future events or otherwise.